Compare Citius Pharmaceuticals Inc (CTXR) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while IQIYI Inc - ADR trades at $1.02 (market cap $974.67M). The key difference: IQIYI Inc - ADR is far larger — about 71.6× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 4,964,108). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and IQIYI Inc - ADR for 55 Days on average.
| CTXR | IQ | |
|---|---|---|
Market Cap | $13.62M | $974.67M |
Volume | 132,438 | 4,964,108 |
Sector | Health | Media |
52-Week High | $1.82 | $2.35 |
52-Week Low | $0.48 | $0.86 |
Typical Hold Time | 16 Days | 55 Days |
Enterprise Value | $3.79M | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
IQ trades at $1.015, up 0.5% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29 billion, and negative profit margins persist. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights iQIYI's focus on AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious due to revenue contraction and recurring losses, though AI initiatives offer growth potential. Key risks include competitive pressures in streaming and reliance on Chinese market dynamics. Institutional ownership trends and earnings performance in upcoming quarters will be critical for stock direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
